{"id":6355,"date":"2025-01-08T21:36:27","date_gmt":"2025-01-08T21:36:27","guid":{"rendered":"https:\/\/afiyafrica.com\/?p=6355"},"modified":"2025-01-08T21:37:16","modified_gmt":"2025-01-08T21:37:16","slug":"loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax","status":"publish","type":"post","link":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/","title":{"rendered":"L’OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax"},"content":{"rendered":"
\n
\n \t<\/i> Read Time:<\/span>3 Minute, 32 Second <\/div>\n\n <\/div>

Le 18 d\u00e9cembre 2024, l\u2019Organisation mondiale de la sant\u00e9 (OMS) a pr\u00e9qualifi\u00e9 le premier test de diagnostic du d\u00e9ficit en glucose-6-phosphate d\u00e9shydrog\u00e9nase (G6PD) qui peut aider \u00e0 administrer en toute s\u00e9curit\u00e9 les traitements recommand\u00e9s par l\u2019OMS pour pr\u00e9venir les rechutes de l\u2019infection \u00e0 Plasmodium vivax ( P. vivax ).<\/p>\n

 <\/p>\n

La pr\u00e9qualification de ce test de diagnostic G6PD marque une \u00e9tape importante dans la mise en place d’un traitement s\u00fbr et efficace du paludisme \u00e0 P. vivax , r\u00e9affirmant la d\u00e9termination de l’OMS \u00e0 garantir un acc\u00e8s \u00e9quitable \u00e0 des solutions de sant\u00e9 vitales \u00e0 l’\u00e9chelle mondiale. Environ 500 000 personnes meurent chaque ann\u00e9e du paludisme, la plupart \u00e9tant des enfants.<\/p>\n

 <\/p>\n

La pr\u00e9qualification de ce test a imm\u00e9diatement suivi la pr\u00e9qualification, d\u00e9but d\u00e9cembre, de deux nouveaux produits \u00e0 base de taf\u00e9noquine pour le traitement anti-rechute du paludisme \u00e0 P. vivax , et ces produits th\u00e9rapeutiques ont \u00e9t\u00e9 recommand\u00e9s dans les directives actualis\u00e9es de l’OMS sur le paludisme publi\u00e9es quelques jours plus t\u00f4t, fin novembre.<\/p>\n

 <\/p>\n

Cet ensemble de mesures de l\u2019OMS refl\u00e8te l\u2019adoption r\u00e9cente par l\u2019organisation de processus synchronis\u00e9s et parall\u00e8les pour deux fonctions cl\u00e9s : l\u2019\u00e9laboration de recommandations pour les produits de sant\u00e9 essentiels et la supervision de leur pr\u00e9qualification.<\/p>\n

 <\/p>\n

Bien que ces processus restent enti\u00e8rement ind\u00e9pendants, leur harmonisation vise \u00e0 r\u00e9duire consid\u00e9rablement le temps n\u00e9cessaire pour acheminer des produits de sant\u00e9 essentiels vers les pays \u00e0 revenu faible ou interm\u00e9diaire de la tranche inf\u00e9rieure. Cette approche simplifi\u00e9e souligne l’engagement de l’OMS \u00e0 am\u00e9liorer l’\u00e9quit\u00e9 en mati\u00e8re de sant\u00e9 mondiale en acc\u00e9l\u00e9rant l’acc\u00e8s \u00e0 des produits vitaux.<\/p>\n

 <\/p>\n

Le paludisme \u00e0 P. vivax est end\u00e9mique dans toutes les r\u00e9gions de l\u2019OMS, \u00e0 l\u2019exception de la r\u00e9gion europ\u00e9enne, avec environ 9,2 millions de cas cliniques survenus en 2023. P. vivax est le parasite dominant du paludisme dans la plupart des pays en dehors de l\u2019Afrique subsaharienne .<\/p>\n

 <\/p>\n

Le d\u00e9ficit en G6PD, une maladie g\u00e9n\u00e9tique, touche plus de 500 millions de personnes. Si la plupart des personnes atteintes ignorent leur d\u00e9ficit en G6PD et passent leur vie sans souffrir d\u2019effets secondaires, certains m\u00e9dicaments administr\u00e9s pour pr\u00e9venir les rechutes du paludisme caus\u00e9 par P. vivax peuvent entra\u00eener une h\u00e9molyse aigu\u00eb (destruction des globules rouges). En l\u2019absence de tests de d\u00e9pistage du G6PD accessibles et fiables, il est difficile de fournir des traitements anti-rechute en toute s\u00e9curit\u00e9, ce qui limite l\u2019utilisation g\u00e9n\u00e9ralis\u00e9e de cette th\u00e9rapie efficace.<\/p>\n

 <\/p>\n

\u00ab La pr\u00e9qualification de ce test enzymatique G6PD pour les patients atteints de paludisme \u00e0 P. vivax peut aider les pays \u00e0 am\u00e9liorer l\u2019acc\u00e8s \u00e0 des tests de qualit\u00e9 dont ils ont tant besoin, permettant ainsi un traitement et une pr\u00e9vention s\u00fbrs et efficaces de ce type de paludisme r\u00e9current \u00bb, a d\u00e9clar\u00e9 le Dr Yukiko Nakatani, Sous-Directrice g\u00e9n\u00e9rale de l\u2019OMS charg\u00e9e de l\u2019acc\u00e8s aux m\u00e9dicaments et aux produits de sant\u00e9. \u00ab Actuellement, aucune autre demande de pr\u00e9qualification n\u2019a \u00e9t\u00e9 re\u00e7ue pour ce type de test. Nous encourageons la soumission de produits suppl\u00e9mentaires pour \u00e9largir la gamme d\u2019outils de diagnostic efficaces \u00e0 la disposition des pays qui en ont besoin. \u00bb<\/p>\n

 <\/p>\n

\u00ab Une plus grande disponibilit\u00e9 du test peut contribuer \u00e0 renforcer la r\u00e9ponse mondiale au paludisme en r\u00e9duisant le nombre d’ infections \u00e0 P. vivax dues aux rechutes et, par cons\u00e9quent, en r\u00e9duisant la transmission ult\u00e9rieure \u00bb, a d\u00e9clar\u00e9 le Dr Daniel Ngamije Madandi, directeur du Programme mondial de lutte contre le paludisme de l’OMS.<\/p>\n

 <\/p>\n

Les dispositifs de test capables de distinguer avec pr\u00e9cision les patients dont les niveaux d\u2019activit\u00e9 de la G6PD sont sup\u00e9rieurs et inf\u00e9rieurs aux niveaux normaux fournissent des informations essentielles aux cliniciens pour d\u00e9cider lequel des sch\u00e9mas th\u00e9rapeutiques anti-rechute de P. vivax est le plus appropri\u00e9, y compris la primaquine \u00e0 faible et \u00e0 forte dose et la taf\u00e9noquine \u00e0 dose unique.<\/p>\n

 <\/p>\n

L’outil de diagnostic STANDARD G6PD System fabriqu\u00e9 par SD Biosensor, Inc. est une solution semi-quantitative, proche du patient, con\u00e7ue pour la mesure de l’activit\u00e9 enzymatique G6PD dans le sang total capillaire ou veineux. L’appareil est destin\u00e9 \u00e0 \u00eatre utilis\u00e9 en laboratoire et hors laboratoire et fonctionne avec l’analyseur STANDARD G6PD, un appareil portatif, qui fournit des r\u00e9sultats en quelques minutes.<\/p>\n

 <\/p>\n

Organisation Mondiale de la Sant\u00e9<\/p>\n

\n
\n \n
\n \n \"Happy\"\n <\/a>\n
\n Happy <\/div>\n
\n 0<\/span>\n \n 0<\/span> %<\/span>\n <\/div>\n <\/div>\n\n
\n \n \"Sad\"\n <\/a>\n
\n Sad <\/div>\n
\n 0<\/span>\n 0<\/span> %<\/span>\n <\/div>\n <\/div>\n\n
\n \n \"Excited\"\n <\/a>\n
\n Excited <\/div>\n
\n 0<\/span>\n 0<\/span> %<\/span>\n <\/div>\n <\/div>\n\n
\n \n \"Sleepy\"\n <\/a>\n
\n Sleepy <\/div>\n
\n 0<\/span>\n \n 0<\/span> %<\/span>\n <\/div>\n <\/div>\n\n
\n \n \"Angry\"\n <\/a>\n
Angry<\/div>\n
\n 0<\/span>\n 0<\/span> %<\/span>\n \n <\/div>\n <\/div>\n\n
\n \n \"Surprise\"\n <\/a>\n
Surprise<\/div>\n
\n 0<\/span>\n 0<\/span> %<\/span>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n ","protected":false},"excerpt":{"rendered":"

Le 18 d\u00e9cembre 2024, l\u2019Organisation mondiale de la sant\u00e9 (OMS) a pr\u00e9qualifi\u00e9 le premier test…<\/p>\n","protected":false},"author":4,"featured_media":6357,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12],"tags":[1188,1071,1214,1337,31,60,32,120,1680,105,1678,1682],"class_list":["post-6355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite","tag-actualites","tag-actumed","tag-afiya","tag-afiyafrica","tag-afrique","tag-afrique-sante","tag-oms","tag-oms-afrique","tag-p-vivax","tag-paludisme","tag-plasmodium-vivax","tag-test-diagnostic"],"yoast_head":"\nL'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -\" \/>\n<meta property=\"og:description\" content=\"Le 18 d\u00e9cembre 2024, l\u2019Organisation mondiale de la sant\u00e9 (OMS) a pr\u00e9qualifi\u00e9 le premier test...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T21:36:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T21:37:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"299\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Afiya Africa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Afiya Africa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/\",\"url\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/\",\"name\":\"L'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -\",\"isPartOf\":{\"@id\":\"https:\/\/afiyafrica.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg\",\"datePublished\":\"2025-01-08T21:36:27+00:00\",\"dateModified\":\"2025-01-08T21:37:16+00:00\",\"author\":{\"@id\":\"https:\/\/afiyafrica.com\/#\/schema\/person\/214bc1623c9d3742df50298a765c4dec\"},\"breadcrumb\":{\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage\",\"url\":\"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg\",\"contentUrl\":\"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg\",\"width\":299,\"height\":168},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/afiyafrica.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L’OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/afiyafrica.com\/#website\",\"url\":\"https:\/\/afiyafrica.com\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/afiyafrica.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/afiyafrica.com\/#\/schema\/person\/214bc1623c9d3742df50298a765c4dec\",\"name\":\"Afiya Africa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/afiyafrica.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d3b666b3619239f23c99ceed618c91e123b81900258fb5aed47318848e25bfeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d3b666b3619239f23c99ceed618c91e123b81900258fb5aed47318848e25bfeb?s=96&d=mm&r=g\",\"caption\":\"Afiya Africa\"},\"url\":\"https:\/\/afiyafrica.com\/index.php\/author\/afiyafrica\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/","og_locale":"fr_FR","og_type":"article","og_title":"L'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -","og_description":"Le 18 d\u00e9cembre 2024, l\u2019Organisation mondiale de la sant\u00e9 (OMS) a pr\u00e9qualifi\u00e9 le premier test...","og_url":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/","article_published_time":"2025-01-08T21:36:27+00:00","article_modified_time":"2025-01-08T21:37:16+00:00","og_image":[{"width":299,"height":168,"url":"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg","type":"image\/jpeg"}],"author":"Afiya Africa","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Afiya Africa","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/","url":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/","name":"L'OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax -","isPartOf":{"@id":"https:\/\/afiyafrica.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage"},"image":{"@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage"},"thumbnailUrl":"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg","datePublished":"2025-01-08T21:36:27+00:00","dateModified":"2025-01-08T21:37:16+00:00","author":{"@id":"https:\/\/afiyafrica.com\/#\/schema\/person\/214bc1623c9d3742df50298a765c4dec"},"breadcrumb":{"@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#primaryimage","url":"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg","contentUrl":"https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg","width":299,"height":168},{"@type":"BreadcrumbList","@id":"https:\/\/afiyafrica.com\/index.php\/actualite\/loms-prequalifie-un-test-de-diagnostic-pour-favoriser-une-administration-plus-sure-des-traitements-contre-le-paludisme-a-p-vivax\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/afiyafrica.com\/"},{"@type":"ListItem","position":2,"name":"L’OMS pr\u00e9qualifie un test de diagnostic pour favoriser une administration plus s\u00fbre des traitements contre le paludisme \u00e0 P. vivax"}]},{"@type":"WebSite","@id":"https:\/\/afiyafrica.com\/#website","url":"https:\/\/afiyafrica.com\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/afiyafrica.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/afiyafrica.com\/#\/schema\/person\/214bc1623c9d3742df50298a765c4dec","name":"Afiya Africa","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/afiyafrica.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d3b666b3619239f23c99ceed618c91e123b81900258fb5aed47318848e25bfeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d3b666b3619239f23c99ceed618c91e123b81900258fb5aed47318848e25bfeb?s=96&d=mm&r=g","caption":"Afiya Africa"},"url":"https:\/\/afiyafrica.com\/index.php\/author\/afiyafrica\/"}]}},"featured_image_urls":{"full":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"thumbnail":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5-150x150.jpeg",150,150,true],"medium":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"medium_large":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"large":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"rpg_image_slider":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"rpg_image_thumbnail":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"1536x1536":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"2048x2048":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"enternews-slider-full":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"enternews-featured":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false],"enternews-medium":["https:\/\/afiyafrica.com\/wp-content\/uploads\/2025\/01\/telechargement-5.jpeg",299,168,false]},"author_info":{"display_name":"Afiya Africa","author_link":"https:\/\/afiyafrica.com\/index.php\/author\/afiyafrica\/"},"category_info":"<a href=\"https:\/\/afiyafrica.com\/index.php\/category\/actualite\/\" rel=\"category tag\">Actualit\u00e9<\/a>","tag_info":"Actualit\u00e9","comment_count":"0","_links":{"self":[{"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/posts\/6355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/comments?post=6355"}],"version-history":[{"count":1,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/posts\/6355\/revisions"}],"predecessor-version":[{"id":6356,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/posts\/6355\/revisions\/6356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/media\/6357"}],"wp:attachment":[{"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/media?parent=6355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/categories?post=6355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/afiyafrica.com\/index.php\/wp-json\/wp\/v2\/tags?post=6355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}